A Phase 1/2 interventional study of EC-18 in Febrile Neutropenia, sponsored by Enzychem Lifesciences Corporation. Completed at 3 sites in South Korea. Open to female participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Enzychem Lifesciences Corporation · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To assess the safety and establish the dose to assess the pharmacokinetic activity following administration of EC-18 in patients with advanced breast cancer receiving low febrile neutropenia risk chemotherapy who are the candidates for second-line or higher combination therapy with doxorubicin and cyclophosphamide.
This study will utilize a non-randomized, open-label 3 + 3 dose escalation design in which subjects will receive 500 mg, 1000 mg, 1500 mg, 2000 mg, 3000 mg and 4000mg of EC-18. The stepwise daily dosing by cohort was performed for 21 days (3 weeks)
147 studies on the registry are indexed under Febrile Neutropenia; 36 are open to participants now.
This study's enrollment of 28 is below the median of 120 across 95 interventional studies indexed under Febrile Neutropenia.
Browse Febrile Neutropenia studies →Enzychem Lifesciences Corporation is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects with adequate function of major organs based on the following clinical laboratory values in the latest test performed within 28 days prior to IP dosing:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
EC-18 500 mg
Drug: EC-18
EC-18 1000 mg
Drug: EC-18
EC-18 1500 mg
Drug: EC-18
EC-18 2000 mg
Drug: EC-18
EC-18 3000 mg
Drug: EC-18
EC-18 4000 mg
Drug: EC-18
oral administration
Also known as: EC-18 soft capsules
Duration of Grade 4 Neutropenia
Duration of Grade 4 neutropenia during Cycle 1 of chemotherapy, based on absolute neutrophil count (ANC) assessed using NCI CTCAE v4.03.
Time frame: During Cycle 1 of chemotherapy (up to 21 days)
Number of Participants With Grade 3-4 Neutropenia
Neutropenia was graded according to NCI CTCAE v4.03. This outcome reports the number of participants who experienced Grade 3 or Grade 4 neutropenia during Cycle 1 of chemotherapy.
Time frame: During Cycle 1 of chemotherapy
Number of Participants With Febrile Neutropenia
Febrile neutropenia was assessed based on absolute neutrophil count (ANC) and body temperature according to NCI CTCAE v4.03. This outcome reports the number of participants who experienced febrile neutropenia during the study period.
Time frame: For 15 days after starting chemotherapy (except for Days 3 and 4).
Number of Participants With Treatment-Emergent Adverse Events
Treatment-emergent adverse events (TEAEs) were assessed from initiation of EC-18 treatment through the end of the final follow-up period. This outcome reports the number of participants who experienced at least one TEAE. Adverse events were graded according to NCI CTCAE v4.03.
Time frame: From first dose of EC-18 through the final safety follow-up visit (3-week treatment period and follow-up visit at Day 36)
Clinical Laboratory Evaluations
Clinical laboratory tests (hematology, clinical chemistry, coagulation, and urine test result analysis) -- absolute values and changes from the baseline
Time frame: 3-week treatment period and follow-up visit at day 36
Vital Signs
Absolute values and changes from baseline in vital signs
Time frame: 3-week treatment period and follow-up visit at day 36
12-lead Electrocardiogram (ECG)
Absolute values and changes from baseline ECG
Time frame: 3-week treatment period and follow-up visit
This clinical study was conducted in women with advanced breast cancer receiving low febrile neutropenia risk chemotherapy.
| Milestone | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 |
|---|---|---|---|---|---|---|
| Started | 7 | 3 | 4 | 6 | 4 | 4 |
| Completed | 3 | 3 | 3 | 3 | 1 | 3 |
| Not completed | 4 | 0 | 1 | 3 | 3 | 1 |
Duration of Grade 4 neutropenia during Cycle 1 of chemotherapy, based on absolute neutrophil count (ANC) assessed using NCI CTCAE v4.03.
| Days | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 |
|---|---|---|---|---|---|---|
| Duration of Grade 4 Neutropenia | 4.8 ± 1.9 | 6.0 ± 2.6 | 4.0 ± 2.2 | 4.2 ± 1.3 | 4.3 ± 1.5 | 4.8 ± 1.7 |
Neutropenia was graded according to NCI CTCAE v4.03. This outcome reports the number of participants who experienced Grade 3 or Grade 4 neutropenia during Cycle 1 of chemotherapy.
| Participants | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 |
|---|---|---|---|---|---|---|
| Number of Participants With Grade 3-4 Neutropenia | 6 | 3 | 4 | 6 | 3 | 4 |
Febrile neutropenia was assessed based on absolute neutrophil count (ANC) and body temperature according to NCI CTCAE v4.03. This outcome reports the number of participants who experienced febrile neutropenia during the study period.
| Participants | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 |
|---|---|---|---|---|---|---|
| Number of Participants With Febrile Neutropenia | 4 | 0 | 1 | 3 | 3 | 1 |
Treatment-emergent adverse events (TEAEs) were assessed from initiation of EC-18 treatment through the end of the final follow-up period. This outcome reports the number of participants who experienced at least one TEAE. Adverse events were graded according to NCI CTCAE v4.03.
| Participants | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 |
|---|---|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events | 7 | 3 | 4 | 6 | 4 | 4 |
Clinical laboratory tests (hematology, clinical chemistry, coagulation, and urine test result analysis) -- absolute values and changes from the baseline
No measurements were reported for this outcome.
Absolute values and changes from baseline in vital signs
No measurements were reported for this outcome.
Absolute values and changes from baseline ECG
No measurements were reported for this outcome.
Collected over From screening until the end of follow up at day 36 +/- 2 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 | 0/7 (0%) | 4/7 (57.1%) | 7/7 (100%) |
| Cohort 2 | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Cohort 3 | 0/4 (0%) | 1/4 (25%) | 4/4 (100%) |
| Cohort 4 | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Cohort 5 | 0/4 (0%) | 2/4 (50%) | 4/4 (100%) |
| Cohort 6 | 0/4 (0%) | 1/4 (25%) | 4/4 (100%) |
| Event | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 |
|---|---|---|---|---|---|---|
| Febrile NeutropeniaBlood and lymphatic system disorders | 4/7 | 0/3 | 1/4 | 2/6 | 2/4 | 0/4 |
| NeutropeniaBlood and lymphatic system disorders | 0/7 | 0/3 | 0/4 | 0/6 | 0/4 | 1/4 |
| Event | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 |
|---|---|---|---|---|---|---|
| Neutrophil count decreasedInvestigations | 6/7 | 3/3 | 3/4 | 5/6 | 1/4 | 2/4 |
| FatigueGeneral disorders | 6/7 | 2/3 | 0/4 | 1/6 | 3/4 | 0/4 |
| Febrile neutropeniaBlood and lymphatic system disorders | 4/7 | 0/3 | 1/4 | 3/6 | 3/4 | 1/4 |
| NauseaGastrointestinal disorders | 2/7 | 2/3 | 2/4 | 2/6 | 3/4 | 3/4 |
| ConstipationGastrointestinal disorders | 0/7 | 0/3 | 0/4 | 4/6 | 1/4 | 1/4 |
| StomatitisGastrointestinal disorders | 4/7 | 2/3 | 0/4 | 1/6 | 0/4 | 2/4 |
| Decreased appetiteMetabolism and nutrition disorders | 3/7 | 2/3 | 0/4 | 0/6 | 0/4 | 1/4 |
| DizzinessNervous system disorders | 1/7 | 2/3 | 0/4 | 0/6 | 0/4 | 1/4 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/7 | 0/3 | 2/4 | 0/6 | 2/4 | 0/4 |
| AlopeciaSkin and subcutaneous tissue disorders | 3/7 | 0/3 | 2/4 | 2/6 | 0/4 | 0/4 |
| Age, Continuous(Years) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 | Total |
|---|---|---|---|---|---|---|---|
| Mean | 55.7 ± 6.9 | 49.3 ± 0.6 | 56.5 ± 6.2 | 57.3 ± 10.5 | 56.0 ± 7.5 | 54.5 ± 5.5 | 55.4 ± 7.1 |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 | Total |
|---|---|---|---|---|---|---|---|
| Female | 7 | 3 | 4 | 6 | 4 | 4 | 28 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race and Ethnicity Not Collected(Participants) | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 | Total |
|---|---|---|---|---|---|---|---|
| Count of participants | — | — | — | — | — | — | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2017 to primary completion in Nov 2019, 24 months.
Results were first posted in Nov 2026, 6 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mosedipimod
Enzychem Lifesciences Corporation